You are in: eMedicine Specialties > Emergency Medicine > OPHTHALMOLOGY Ultraviolet KeratitisArticle Last Updated: Feb 4, 2008AUTHOR AND EDITOR INFORMATIONAuthor: Reed Brozen, MD, Director of Air Transport, Associate Professor, Department of Emergency Medicine, Dartmouth Medical School, Dartmouth-Hitchcock Medical Center Reed Brozen is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, New Hampshire Medical Society, and Society for Academic Emergency Medicine Coauthor(s): Christian Fromm, MD, Director of Research, Department of Emergency Medicine, Maimonides Medical Center, Assistant Professor of Emergency Medicine, Mt Sinai School of Medicine Editors: Eric Kardon, MD, FACEP, Associate Staff, Division of Emergency Medicine, Athens Regional Medical Center; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; James S Walker, DO, Program Coordinator, Associate Professor, Department of Emergency Medicine, University of Oklahoma Health Sciences Center; John D Halamka, MD, MS, Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center; Rick Kulkarni, MD, Medical Director, Assistant Professor of Surgery, Section of Emergency Medicine, Yale-New Haven Hospital Author and Editor Disclosure Synonyms and related keywords: actinic keratitis, snow blindness, flash burn, welder's flash, arc eye, ultraviolet keratitis, UV keratitis, UV radiation injury, corneal damage, corneal abrasion, corneal ulceration, corneal laceration, superficial punctate keratitis, SPK, UV keratoconjunctivitis, ultraviolet keratoconjunctivitis INTRODUCTIONBackgroundUV light is the most common cause of radiation injury to the eye. The cornea absorbs most UV radiation. UV radiation damage to the corneal epithelium is cumulative, similar to the effects with dermal epithelium (sunburn). Ozone in the atmosphere effectively filters most of the harmful UV radiation of wavelengths shorter than 290 nm; natural UV sources, such as the sun, rarely cause injury after short exposures. However, unprotected exposures to the sun or solar eclipses or exposure to the sun on highly reflective snow fields at high elevation can lead to direct corneal epithelial injury. The latter clinical scenario is known as snow blindness. Artificial sources of UV radiation also cause corneal damage. Injury from a welder's arc commonly is known as flash burn, welder's flash, or arc eye. Other sources of UV radiation injury include suntanning beds, carbon arcs, photographic flood lamps, lightning, electric sparks, and halogen desk lamps. Prolonged exposures to UV radiation can lead to chronic solar toxicity, which is associated with several ocular surface disorders, eg, pinguecula, pterygium, climatic droplet keratopathy, and even squamous metaplasia and carcinoma. The only ocular cancer associated with UV radiation is epidermoid carcinoma of the bulbar conjunctiva, which occurs with increased frequency in the tropics and subtropics and which has been experimentally replicated in animal models using UV radiation. Rarely, retinal absorption of visible to near-infrared (400-1400 nm) radiation from welding arcs can lead to permanent, sight-threatening injury. PathophysiologyUV rays irritate the superficial corneal epithelium, causing inhibition of mitosis, production of nuclear fragmentation, and loosening of the epithelial layer. Under experimental conditions in animals, phototoxic effects have been demonstrated at all levels of the cornea, including the stroma and endothelium. An inflammatory response occurs, which includes edema and congestion of the conjunctiva and a stippling of the corneal epithelium known as superficial punctate keratitis (SPK). SPK is a nonspecific corneal condition associated with multiple ocular disorders. It is characterized by small pinpoint defects in the superficial corneal epithelium, which stain with fluorescein. If SPK is severe, it may be followed by total epithelial desquamation, with conjunctival chemosis, lacrimation, and blepharospasm. Reepithelialization usually occurs within 36-72 hours, and long-term sequelae are rare. This SPK contrasts with the more severe effects frequently encountered with corneal damage caused by alkaline or strongly acidic chemicals. In general, ocular pain and decreased visual acuity occurs 6-12 hours after the injury. This lag time involves an unexplained pattern of corneal sensory loss and return and is thought to indicate a probable photochemical injury rather than a thermal injury to the cornea. FrequencyUnited StatesUV keratitis and UV keratoconjunctivitis are the only radiant exposure conditions of the cornea that occur with any significant frequency in the United States. Mortality/MorbidityNo reported mortality exists.
SexNo difference in incidence exists between males and females. CLINICALHistory
PhysicalPrior to examination or treatment, assess visual acuity, with corrective lenses if relevant. Perform a full examination of the eyes, including inspection of all external structures together with funduscopic and slit lamp examinations.
CausesRadiation injury to the eye may be caused by unprotected or long exposures to the sun, particularly at high altitude; exposure to UV radiation reflected off snow, ice, or water; and viewing of solar eclipses. In addition to the sun, sources of UV radiation include the following:
DIFFERENTIALSConjunctivitis Corneal Ulceration and Ulcerative Keratitis Iritis and Uveitis
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Drug Name | Proparacaine 0.5% (Alcaine, Ophthetic) |
|---|---|
| Description | Has rapid onset of anesthesia that begins 13-30 sec after instillation. However, has short duration of action of about 15-20 min. Since prolonged eye anesthesia can eliminate patient's awareness of mechanical damage to the cornea, drug should not be used outside the ED. Frequent use of anesthetics may retard healing. Least irritating of all topical anesthetics. Prevents initiation and transmission of impulse at nerve cell membrane by stabilizing and decreasing ion permeability. |
| Adult Dose | 2-3 gtt in affected eye q15-20min during ED examination |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity; prolonged use |
| Interactions | Increases effects of phenylephrine and tropicamide |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Caution in cardiac disease or hyperthyroidism and with abnormal or reduced levels of plasma esterases |
These agents relax ciliary muscle spasm that can cause a deep aching pain and photophobia. Cycloplegics are used to facilitate eye examination and provide relief of symptoms in patients with moderate-to-severe eye injury. Cycloplegic agents also are mydriatics, thus before using them it is important to ensure that the patient does not have glaucoma. This medication could provoke an acute angle-closure glaucoma attack in a susceptible patient.
| Drug Name | Cyclopentolate 0.5-1% (Cyclogyl) |
|---|---|
| Description | Prevents muscle of ciliary body, and sphincter muscle of iris from responding to cholinergic stimulation. Induces mydriasis in 30-60 min and cycloplegia in 25-75 min. |
| Adult Dose | 1 gtt of 1% solution to induce cycloplegia; repeat in 5-10 min prn |
| Pediatric Dose | <1 year: 1 gtt of 0.5% into each eye 5-10 min before examination >1 year: 1 gtt of 0.5%, 1%, or 2% solution; repeat in 5-10 min prn |
| Contraindications | Documented hypersensitivity; narrow-angle glaucoma |
| Interactions | Decreases effects of carbachol and cholinesterase inhibitors |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Caution in patients (eg, elderly patients) in whom increased intraocular pressure may be present; can cause toxic anticholinergic systemic adverse effects, but incidence is rare when used sparingly (more common in children, especially infants); compressing the lacrimal sac with digital pressure for 1-3 min following application may minimize systemic absorption |
The routine use of topical antibiotics remains controversial. Many emergency physicians have stopped its use for minor injuries, although others continue routine treatment with a broad-spectrum antibiotic ointment for lubrication and infection prophylaxis. This treatment persists despite its unproven efficacy, discomfort, and evidence that ointments may retard corneal epithelial healing.
| Drug Name | Erythromycin 0.5% ointment (Ilotycin, AK-Mycin) |
|---|---|
| Description | Indicated for treatment of infections caused by susceptible strains of microorganisms and for prevention of corneal and conjunctival infections. |
| Adult Dose | Apply 0.5-inch (1.25-cm) ribbon 2-8 times/d, depending on severity of the infection |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity; viral, mycobacterial, and fungal infections of the eye; patients using steroid combinations after the uncomplicated removal of a foreign body from the cornea should avoid using this product |
| Interactions | None reported |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Not for use to treat ocular infections that are likely to become systemic; prolonged or repeated therapy may result in bacterial or fungal overgrowth of nonsusceptible organisms and may lead to a secondary infection; take appropriate measures if superinfection occurs |
| Drug Name | Gentamicin (Genoptic, Garamycin) |
|---|---|
| Description | Aminoglycoside antibiotic used for gram-negative bacterial coverage. |
| Adult Dose | Ointment: Apply 0.5-inch (1.25-cm) ribbon bid/tid to the affected eye q3-4h Solution: 1-2 gtt in affected eye q2-4h, as often as q1h for severe infections |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity; mycobacterial, viral, and fungal infections of the eye; patients taking steroid combinations after uncomplicated removal of a foreign body from cornea should also avoid using this product |
| Interactions | None reported |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Do not use to treat ocular infections that may become systemic; prolonged or repeated antibiotic therapy may result in bacterial or fungal overgrowth of nonsusceptible organisms that may lead to a secondary infection; take appropriate measures if superinfection occurs |
Although most NSAIDs are used primarily for their anti-inflammatory effects, they are effective analgesics and are useful for the relief of mild to moderate pain. Pain control is essential to quality patient care. Although oral narcotics may be sedating they should be prescribed and are nearly always needed to gain adequate pain control. Prescribing adequate pain medications on the first visit is essential to prevent a revisit solely for pain control. Only a small quantity is needed since this is a self-limited problem with short duration.
| Drug Name | Ibuprofen (Motrin, Advil, Nuprin, Rufen) |
|---|---|
| Description | Usually the DOC for mild to moderate pain, if no contraindications exist; inhibits inflammatory reactions and pain, probably by decreasing cyclooxygenase activity, which results in the inhibition of prostaglandin synthesis |
| Adult Dose | 200-800 mg PO q4-6h, while symptoms persist; not to exceed 3.2 g/d |
| Pediatric Dose | 10-70 mg/kg/d PO divided tid/qid |
| Contraindications | Documented hypersensitivity; because of potential cross-sensitivity to other NSAIDs, do not give these agents to patients in whom aspirin, iodides, or other NSAIDs induce hypersensitivity; peptic ulcer disease; recent GI bleeding or perforation; renal insufficiency; high risk of bleeding |
| Interactions | Probenecid may increase the concentrations and possibly the toxicity; may decrease the effect of loop diuretics when administered concurrently; PT may increase when administered concurrently with anticoagulants (monitor PT closely, and instruct patients to watch for signs and symptoms of bleeding); may increase serum lithium levels and risk of methotrexate toxicity |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus |
| Precautions | Caution in congestive heart failure, hypertension, and decreased renal and hepatic function |
| Drug Name | Oxycodone and acetaminophen (Percocet, Tylox, Roxicet) |
|---|---|
| Description | Drug combination indicated for the relief of moderate to severe pain. |
| Adult Dose | 1-2 tab or cap PO q4-6h prn |
| Pediatric Dose | 0.05-0.15 mg/kg/dose PO q4-6h prn; not to exceed 5 mg/dose of oxycodone |
| Contraindications | Documented hypersensitivity |
| Interactions | Phenothiazines may decrease analgesic effects; toxicity increases when administered concurrently with CNS depressants or tricyclic antidepressants |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Duration of action may increase in elderly patients; be aware of the total daily dose of acetaminophen; maximum dose of acetaminophen is 4,000 mg/d, higher doses may cause liver toxicity |
Some ophthalmologists are advocating that diclofenac (Voltaren) or ketorolac (Acular) drops be used despite lack of official indications. These topical agents have been shown to relieve pain in multiple situations including corneal abrasions, allergies, and postsurgical pain.
| Drug Name | Ketorolac tromethamine 0.5% (Acular) |
|---|---|
| Description | Inhibits prostaglandin synthesis by decreasing activity of the enzyme, cyclooxygenase, which results in decreased formation of prostaglandin precursors, which, in turn, results in reduced inflammation. |
| Adult Dose | 1 gtt into each affected eye qid, continue for a maximum of 2 wk |
| Pediatric Dose | <12 years: Not established >12 years: Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | None reported |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Perform ophthalmologic studies in patients who develop eye complaints during therapy; discontinue therapy if changes are noted; changes may include blurred or diminished vision, corneal deposits and retinal disturbances, scotomata, changes in color vision, and macula degeneration |
| Drug Name | Diclofenac (Voltaren) |
|---|---|
| Description | Inhibits prostaglandin synthesis by decreasing the activity of the enzyme cyclooxygenase, which results in decreased formation of prostaglandin precursors. |
| Adult Dose | 1 gtt into affected eye qid, continue for a maximum of 2 wk |
| Pediatric Dose | <12 years: Not established >12 years: Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | None reported |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Corneal thinning may occur |
The authors and editors of eMedicine gratefully acknowledge the contributions of previous editor, Craig Feied, MD, to the development and writing of this article.
| Media file 1: Ultraviolet keratitis. Diffuse uptake of fluorescein stain as seen in ultraviolet keratitis. | |
![]() | View Full Size Image | Media type: Photo |
Article Last Updated: Feb 4, 2008